选择性五羟色胺再摄取抑制剂对骨骼系统及口腔种植体骨结合影响的研究进展

doi:10.12337/zgkqzzxzz.2022.04.013

摘要/Abstract

摘要： 选择性五羟色胺再摄取抑制剂（selective serotonin reuptake inhibitor,SSRI）是目前临床使用最为广泛的抗抑郁药物。现有研究显示SSRI可破坏成骨功能,降低骨密度,抑制骨愈合,并可能抑制植入物骨结合。本文介绍了SSRI的药理作用、对骨骼的影响及其机制,并就SSRI的使用与口腔种植失败的关系的研究现状进行探讨。

关键词: 抗抑郁药物, 种植失败, SSRI, 骨结合

Abstract: Selective serotonin reuptake inhibitor (SSRI) is the most widely used antidepressant. Existing studies have shown that SSRI impairs osteogenic function, reduces bone mineral density, inhibits bone healing, and may inhibit osseointegration of implants. This article introduces the pharmacological action of SSRI, its effect on skeletal system and its mechanism, and discusses the research status of oral implant failure related to SSRI use.

Key words: Antidepressant, Implant failure, SSRI, Osseointegration

李顺顺,等王凤. 选择性五羟色胺再摄取抑制剂对骨骼系统及口腔种植体骨结合影响的研究进展[J]. 中国口腔种植学杂志, 2022, 27(2): 124-129. DOI: 10.12337/zgkqzzxzz.2022.04.013

Li Shunshun, Wang Feng. Effects of selective serotonin reuptake inhibitor on skeletal system and osseointegration of oral implants[J].Chinese Journal of Oral Implantology, 2022, 27(2): 124-129.DOI: 10.12337/zgkqzzxzz.2022.04.013.

参考文献

[1] Silva C, Dos Santos MS, Monteiro J, et al.Is there an association between the use of antidepressants and complications involving dental implants? A systematic review and meta-analysis[J]. Int J Oral Maxillofac Surg, 2021,50(1):96-103. DOI: 10.1016/j.ijom.2020.03.014.
[2] Masand PS, Gupta S.Selective serotonin-reuptake inhibitors: an update[J]. Harv Rev Psychiatry, 1999,7(2):69-84.
[3] 谷建琦, 李娟, 康壮飞. 种植体修复前失败的原因分析[J].现代口腔医学杂志,2019,33(4):246-248.
[4] Chrcanovic BR, Kisch J, Albrektsson T, et al.Factors influencing early dental implant failures[J]. J Dent Res, 2016,95(9):995-1002. DOI: 10.1177/0022034516646098.
[5] Liaw K, Delfini RH, Abrahams JJ.Dental implant complications[J]. Semin Ultrasound CT MR, 2015, 36(5): 427-433. DOI: 10.1053/j.sult.2015.09. 007.
[6] Do TA, Le HS, Shen YW, et al.Risk factors related to late failure of dental implant-a systematic review of recent studies[J]. Int J Environ Res Public Health, 2020,17(11):3931.DOI: 10.3390/ijerph17113931.
[7] Chappuis V, Avila-Ortiz G, Araújo MG, et al. Medication-related dental implant failure: systematic review and meta-analysis[J]. Clin Oral Implants Res, 2018,29 Suppl 16:55-68. DOI: 10.1111/clr.13137.
[8] 刘晓晴, 佟富禹. 抗抑郁药的合理应用[J].中国卫生产业, 2016,13(31):192-193. DOI: 10.16659/j.cnki. 1672-5654.2016.31.192.
[9] Wadhwa R, Kumar M, Talegaonkar S, et al.Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms[J]. Osteoporos Sarcopenia, 2017,3(2):75-81. DOI: 10.1016/j.afos.2017.05. 002.
[10] Zhou C, Fang L, Chen Y, et al.Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis[J]. Osteoporos Int, 2018,29(6):1243-1251. DOI: 10.1007/ s00198-018-4413-0.
[11] Larsson B, Mellström D, Johansson L, et al.Normal bone microstructure and density but worse physical function in older women treated with selective serotonin reuptake inhibitors, a cross-sectional population-based study[J]. Calcif Tissue Int, 2018,103(3):278-288. DOI: 10.1007/s00223-018-0427-z.
[12] Zucker I, Chodick G, Grunhaus L, et al.Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study[J]. CNS Drugs, 2012,26(6): 537-547. DOI: 10.2165/11633300-000000000-00000.
[13] Kang S, Han M, Park CI, et al.Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study[J]. Sci Rep, 2021,11(1):13461. DOI: 10.1038/s41598-021-92821-9.
[14] Diem SJ, Ruppert K, Cauley JA, et al.Rates of bone loss among women initiating antidepressant medication use in midlife[J]. J Clin Endocrinol Metab, 2013,98(11):4355-4363. DOI: 10.1210/jc.2013-1971.
[15] Garfield LD, Müller DJ, Kennedy JL, et al.Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults[J]. World J Biol Psychiatry, 2014,15(5):404-410. DOI: 10.3109/15622975.2013. 832380.
[16] Larsson B, Mellström D, Johansson L, et al.Normal bone microstructure and density but worse physical function in older women treated with selective serotonin reuptake inhibitors, a cross-sectional population- based study[J]. Calcif Tissue Int, 2018,103(3):278-288. DOI: 10.1007/s00223-018-0427-z.
[17] Saraykar S, John V, Cao B, et al.Association of selective serotonin reuptake inhibitors and bone mineral density in elderly women[J]. J Clin Densitom, 2018,21(2):193-199. DOI: 10.1016/j.jocd.2017.05.016.
[18] Winterhalder L, Eser P, Widmer J, et al.Changes in volumetric BMD of radius and tibia upon antidepressant drug administration in young depressive patients[J]. J Musculoskelet Neuronal Interact, 2012,12(4): 224-229.
[19] Feuer AJ, Demmer RT, Thai A, et al.Use of selective serotonin reuptake inhibitors and bone mass in adolescents: an NHANES study[J]. Bone, 2015,78:28-33. DOI: 10.1016/j.bone.2015.04.042.
[20] Kumar M, Bajpai R, Shaik AR, et al.Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2020,76(10):1373-1392. DOI: 10.1007/s00228-020-02893-1.
[21] Vangala C, Niu J, Montez-Rath ME, et al.Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis[J]. Am J Kidney Dis, 2020,75(3):351-360. DOI: 10.1053/j.ajkd.2019.07.015.
[22] Bradaschia-Correa V, Josephson AM, Mehta D, et al.The selective serotonin reuptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice[J]. J Bone Miner Res, 2017,32(4):821-833. DOI: 10.1002/jbmr.3045.
[23] Howie RN, Herberg S, Durham E, et al.Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model[J]. Int J Oral Sci, 2018,10(3):25. DOI: 10.1038/s41368-018-0026-x.
[24] Lee S, Remark LH, Buchalter DB, et al.Propranolol reverses impaired fracture healing response observed with selective serotonin reuptake inhibitor treatment[J]. J Bone Miner Res, 2020,35(5):932-941. DOI: 10.1002/jbmr.3950.
[25] Fraher D, Hodge JM, Collier FM, et al.Citalopram and sertraline exposure compromises embryonic bone development[J]. Mol Psychiatry, 2016,21(5):656-664. DOI: 10.1038/mp.2015.135.
[26] Correia-Leite de Marcelos PG, Regueira LS, Santiago-Jaegger IM, et al. Effects of treatment with fluoxetine on mandibular development: a morphological study in rats[J]. Acta Histochem, 2015,117(6):582-589. DOI: 10.1016/j.acthis.2015.05.005.
[27] Regueira LS, Marcelos PG, Santiago-Jaegger IM, et al.Fluoxetine effects on periodontogenesis: histomorphometrical and immunohistochemical analyses in rats[J]. J Appl Oral Sci, 2017,25(2): 159-167. DOI: 10.1590/1678-77572015-0564.
[28] Weaver SR, Xie C, Charles JF, et al.In utero and lactational exposure to the selective serotonin reuptake Inhibitor fluoxetine compromises pup bones at weaning[J]. Sci Rep, 2019,9(1):238. DOI: 10.1038/s41598-018- 36497-8.
[29] Weaver SR, Hernandez LL.Could use of selective serotonin reuptake inhibitors during lactation cause persistent effects on maternal bone?[J]. J Mammary Gland Biol Neoplasia, 2018,23(1-2):5-25. DOI: 10.1007/s10911- 018-9390-6.
[30] Gupta B, Acharya A, Singh S, et al.Evaluation of jawbone morphology and bone density indices in panoramic radiographs of selective serotonin reuptake inhibitor users: a preliminary study[J]. Dentomaxillofac Radiol, 2019,48(1):20170360. DOI: 10.1259/dmfr. 20170360.
[31] Mirhashemi AH, Ahmad Akhoundi MS, Sheikhzadeh S, et al.Effect of fluoxetine consumption on orthodontic tooth movement in rats[J]. J Dent (Tehran), 2015,12(12):882-889.
[32] Sánchez N, Juárez-Balarezo J, Olhaberry M, et al.Depression and antidepressants during pregnancy: craniofacial defects due to stem/progenitor cell deregulation mediated by serotonin[J]. Front Cell Dev Biol, 2021,9:632766. DOI: 10.3389/fcell.2021.632766.
[33] Cray JJ Jr, Weinberg SM, Parsons TE, et al.Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice[J]. Birth Defects Res A Clin Mol Teratol, 2014,100(12):912-923. DOI: 10.1002/bdra.23323.
[34] Durham E, Jen S, Wang L, et al.Effects of citalopram on sutural and calvarial cell processes[J]. PLoS One, 2015,10(10):e0139719. DOI: 10.1371/journal.pone.0139719.
[35] Kumar M, Jiloha RC, Kataria D, et al.Effect of selective serotonin reuptake inhibitors on markers of bone loss[J]. Psychiatry Res, 2019,276:39-44. DOI: 10.1016/j.psychres.2019.04.006.
[36] Durham E, Zhang Y, LaRue A, et al. Selective serotonin reuptake inhibitors (SSRI) affect murine bone lineage cells[J]. Life Sci, 2020,255:117827. DOI: 10.1016/j.lfs.2020.117827.
[37] Ducy P, Karsenty G.The two faces of serotonin in bone biology[J]. J Cell Biol, 2010,191(1):7-13. DOI: 10.1083/jcb.201006123.
[38] Wadhwa R, Kumar M, Paudel YN, et al.Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study[J]. J Bone Miner Metab, 2019,37(1):36-42. DOI: 10.1007/s00774-018- 0908-1.
[39] Tachi J, Onuma T, Yamaguchi S, et al.Duloxetine suppresses BMP-4-induced release of osteoprotegerin via inhibition of the SMAD signaling pathway in osteoblasts[J]. Biochem Cell Biol, 2021,99(5):578-586. DOI: 10.1139/bcb-2020-0347.
[40] Tachi J, Tokuda H, Onuma T, et al.Duloxetine strengthens osteoblast activation by prostaglandin E(1): upregulation of p38 MAP kinase[J]. Prostaglandins Other Lipid Mediat, 2020,151:106481. DOI: 10.1016/j.prostaglandins.2020.106481.
[41] Ortuño MJ, Robinson ST, Subramanyam P, et al.Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect[J]. Nat Med, 2016,22(10):1170-1179. DOI: 10.1038/nm.4166.
[42] Koura SM, Salama M, El-Hussiny M, et al.Fluoxetine induces direct inhibitory effects on mesenchymal stem cell-derived osteoprogenitor cells independent of serotonin concentration[J]. Mol Med Rep, 2019,19(4):2611-2619. DOI: 10.3892/mmr.2019.9924.
[43] Hodge JM, Wang Y, Berk M, et al.Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function[J]. Biol Psychiatry, 2013,74(1):32-39. DOI: 10.1016/j.biopsych. 2012.11.003.
[44] Chandra P, Roy S, Kumari A, et al.Role of selective serotonin reuptake inhibitors in prognosis dental implants: a retrospective study[J]. J Pharm Bioallied Sci, 2021,13(Suppl 1):S92-S96. DOI: 10.4103/jpbs.JPBS_ 569_20.
[45] Deepa, Mujawar K, Dhillon K, et al. Prognostic implication of selective serotonin reuptake inhibitors in osseointegration of dental implants: a 5-year retrospective study[J]. J Contemp Dent Pract, 2018,19(7):842-846.
[46] Carr AB, Gonzalez R, Jia L, et al.Relationship between selective serotonin reuptake inhibitors and risk of dental implant failure[J]. J Prosthodont, 2019,28(3):252-257. DOI: 10.1111/jopr.13015.
[47] Hakam AE, Vila G, Duarte PM, et al.Effects of different antidepressant classes on dental implant failure: a retrospective clinical study[J]. J Periodontol, 2021,92(2):196-204. DOI: 10.1002/JPER.19-0714.
[48] Altay MA, Sindel A, Özalp Ö, et al.Does the Intake of selective serotonin reuptake inhibitors negatively affect dental implant osseointegration? a retrospective study[J]. J Oral Implantol, 2018,44(4):260-265. DOI: 10.1563/aaid-joi-D-17-00240.
[49] Chrcanovic BR, Kisch J, Albrektsson T, et al.Is the intake of selective serotonin reuptake inhibitors associated with an increased risk of dental implant failure?[J]. Int J Oral Maxillofac Surg, 2017,46(6):782-788. DOI: 10.1016/j.ijom.2017.01.016.
[50] Wu X, Al-Abedalla K, Rastikerdar E, et al.Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study[J]. J Dent Res, 2014,93(11):1054-1061. DOI: 10.1177/0022034514549378.
[51] Cizza G, Primma S, Coyle M, et al.Depression and osteoporosis: a research synthesis with meta-analysis[J]. Horm Metab Res, 2010,42(7):467-482. DOI: 10.1055/s-0030-1252020.